TruScreen Group Limited Share Price
Current Share Price data for TruScreen Group Limited (NZX:TRU ASX:TRU)
Investing in TruScreen is an opportunity to invest in the future health and wellbeing of women around the world.
Cervical cancer can and should be prevented.
TruScreen provides an accurate, real-time primary screening solution.
Our screening solution is ideal for communities that can’t access conventional laboratory-based screening methods. It is affordable and easy to learn.
Our purpose is to ensure that all women of screening age – no matter who or where they are – have access to quality screening.
TruScreen manufactures and owns all rights to the TruScreen Cervical Cancer Screening System. The system comprises a medical device and AI-enabled process designed to detect, in real-time, the presence of pre-cancerous and cancerous tissue on the cervix.
TruScreen’s focus markets are low and-middle income countries (LMICs) where there is a lack of organised cervical cancer screening and the required infrastructure.
TruScreen Latest NZX & ASX Announcements
General | Progress Report
15.12.2021
TruScreen Makes Progress in Key Markets Worldwide
TruScreen Group Limited (NZX/ASX: TRU) (‘TruScreen’ or ‘the Company’) is pleased to provide a market update, outlining the Company’s progress in several of its key target markets.
HALFYR
29.11.2021
TruScreen Half Year Report
TruScreen Group Limited - Interim Unaudited Financial Statements For the Six Months Ended 30 September 2021
HALFYR
29.11.2021
TruScreen Half Year Results
TruScreen Group Limited is pleased to announce its unaudited half year financial results for the period ended 30 September 2021. TruScreen reports according to the New Zealand financial year, which runs from 1 April to 31 March.
MKTUPDTE
20.10.2021
TruScreen Device - Milestones Achieved on Growth Strategy
TruScreen Group Limited is pleased to announce the achievement of key milestones relating to the ongoing development of the Company’s women’s health care technology and its overseas growth strategy.
GENERAL
20.10.2021
Clinical Trial Results Highlight Efficacy of TRU Technology
TruScreen Group Limited is pleased to inform the market of a study conducted in China, the results of which indicate that TruScreen’s cervical cancer screening technology has demonstrated to be an effective alternative to cervical cytology.
SECISSUE
30.9.2021
Director and Officer Disclosure Notice
Director and Officer Disclosure Notice - Dexter Cheung
MEETING
9.9.2021
Recording of TruScreen Group Limited Virtual ASM
The Annual Shareholder Meeting of Truscreen Group Limited (NZX:TRU) was held online on 7 September 2021 on Link Market Services virtual platform.
MEETING
7.9.2021
Shareholder Meeting Results
The Annual Meeting of Shareholders of Truscreen Group Limited (NZX:TRU)(ASX:TRU) was held today 7 September 2021. All resolutions were passed by a poll of shareholders present and by registered proxy.
MEETING
7.9.2021
Annual Meeting Presentation
The attached presentation will be delivered at the Annual Meeting of Shareholders to be held today at 11am New Zealand time
GENERAL
1.9.2021
TruScreen Stakeholder August Newsletter
This gives an update on TruScreen's performance and highlights key initiatives underway.
MEETING
5.8.2021
Notice of General Meeting
Notice is hereby given that the Annual Meeting of Shareholders of Truscreen Group Limited will be held as a virtual meeting Online on Tuesday 7 September 2021 at 11.00am, Auckland time.
MEETING
5.8.2021
Chairman's Letter
I am pleased to invite shareholders to the 2021 Annual Meeting (AM) of TruScreen Group Limited. scheduled for 7 September 2021.
GENERAL
1.7.2021
First Sales Made In Eastern Europe
TruScreen is pleased to advise that it has received its first order from Serbia, Eastern Europe.
ANNREP
30.6.2021
TruScreen Annual Report 31 March 2021
TruScreen Limited (NZX: TRU) has released its Annual Report for the year ended 31 March 2021.
SHINTR
11.6.2021
CEO Interview with Stocks Down Under
TruScreen CEO Juliet Hull, sat down and spoke to Stocks Down Under about the opportunity for the TruScreen technology in emerging markets to provide a lower cost and more patient-friendly alternative for cervical cancer screening.
GENERAL
6.5.2021
Stakeholder May Newsletter
This gives an update on TruScreen's performance and highlights key initiatives underway.
GENERAL
24.3.2021
Research Confirms TruScreen's Suitability in COVID-19 Environment
TruScreen is pleased to report that its TruScreen cervical cancer screening device continues to gain recognition around the world.
TruScreen Group Limited Announcements
TruScreen Group is dual-listed on the NZX and ASX. All of our announcements are available through our website, or via the NZX and ASX platforms.
View announcementsMeet the Team
TruScreen has a wealth of experienced, highly skilled professionals across its Directors, Executive Team, Medical Advisory Board, and Research & Development Team.